Who are Mogamulizumab-Kpkc's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Poteligeo, Poteligeo, MK-4280, MK-4280A.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/mogamulizumab-kpkc.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Mogamulizumab-Kpkc — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Mogamulizumab-Kpkc (Mogamulizumab-Kpkc) competitive landscape: 4 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Chemokine Receptor Type 4 Interaction [EPC]. Area: Oncology.

discontinued Chemokine Receptor Type 4 Interaction [EPC] C-C chemokine receptor type 4 Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Mogamulizumab-Kpkc (Mogamulizumab-Kpkc) — H. Lee Moffitt Cancer Center and Research Institute. 12.1 Mechanism of Action Mogamulizumab-kpkc is a defucosylated, humanized IgG1 kappa monoclonal antibody that binds to CCR4, a G protein-coupled receptor for CC chemokines that is involved in the trafficking of lymphocytes to various organs. Non-clinical in vitro studies demonstrate mogamulizumab-kpkc binding targets a cell for antibody-dependent cellular cytotoxicity (ADCC) resulting in depletion of the target cells. CCR4 is expressed on the surface of some T-cell malignancies and is expressed on regulatory T-cells (Treg) and a subset of Th2 T-cells.

Comparator set (4 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Mogamulizumab-Kpkc TARGET	Mogamulizumab-Kpkc	H. Lee Moffitt Cancer Center and Research Institute	discontinued	Chemokine Receptor Type 4 Interaction [EPC]	C-C chemokine receptor type 4
Poteligeo	MOGAMULIZUMAB	Kyowa Kirin	marketed	Chemokine Receptor Type 4 Interaction [EPC]	C-C chemokine receptor type 4	2018-01-01
Poteligeo	Poteligeo	Kyowa Kirin Pharmaceutical Development Ltd	marketed		C-C chemokine receptor type 4
MK-4280	MK-4280	Merck Sharp & Dohme LLC	phase 3	CCR4 antagonist	CCR4 (C-C chemokine receptor type 4)
MK-4280A	MK-4280A	Merck Sharp & Dohme LLC	phase 3	CCR4 antagonist	CCR4 (C-C chemokine receptor type 4)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Chemokine Receptor Type 4 Interaction [EPC] class)

H. Lee Moffitt Cancer Center and Research Institute · 1 drug in this class
Kyowa Kirin · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Mogamulizumab-Kpkc — Competitive Intelligence Brief. https://druglandscape.com/ci/mogamulizumab-kpkc. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab